Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome

被引:0
|
作者
Binnaz Yasar
Helen J Byers
Miriam J Smith
John Lear
Deemesh Oudit
Zaynab Bholah
Stephen A Roberts
William G Newman
D Gareth Evans
机构
[1] Manchester Centre for Genomic Medicine,Department of Genetic Medicine
[2] University of Manchester,Department of Dermatology
[3] Manchester Academic Health Sciences Centre (MAHSC),Department of Surgery
[4] Manchester Centre for Genomic Medicine,undefined
[5] MAHSC,undefined
[6] St Mary's Hospital,undefined
[7] Central Manchester University Hospitals NHS Foundation Trust (CMFT),undefined
[8] Central Manchester University Hospitals NHS Foundation Trust (CMFT),undefined
[9] The Christie NHS Foundation Trust,undefined
[10] MAHSC,undefined
[11] Centre for Biostatistics,undefined
[12] Institute of Population Health,undefined
[13] University of Manchester,undefined
来源
European Journal of Human Genetics | 2015年 / 23卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Gorlin syndrome is an autosomal dominant disorder, characterized by multiple early-onset basal cell carcinomas (BCCs) and jaw keratocysts. Through association studies in cohorts of sporadic BCC, nine genetic variants have previously been identified to increase the risk of BCC. The nine SNPs were genotyped by Taqman allelic discrimination in 125 individuals with Gorlin syndrome. Kaplan–Meier survival curves and Cox proportional-Hazard regression analysis were applied to determine the association between genotypes and age of first BCC in individuals with Gorlin syndrome. The p.(Arg151Cys) variant in MC1R (rs1805007) was associated with an earlier median age of onset of BCC of 27 years (95% CI: 20–34) compared with 34 years (95% CI: 30–40) for wild-type individuals (hazard ratio (HR)=1.64, 95% CI: 1.04–2.58, P=0.034). The risk allele of the variant at the chromosome 5p15 locus encompassing TERT-CLPTM1L (rs401681) was also associated with an earlier median onset of BCC, 31 years (95% CI: 28–37) compared with 41 years (95% CI: 32–48, HR=1.44, 95% CI: 1.08–1.93, P=0.014). In individuals with a risk allele at either rs1805007 or rs401681 the median time to BCC was 31 years of age (95% CI: 28–34) compared with 44 years of age (95% CI: 38–53) in wild-type individuals (HR=2.48, 95% CI: 1.47–4.17, P=0.0002). Our findings may have implications for future personalized risk estimates and BCC screening strategies in individuals with Gorlin syndrome.
引用
收藏
页码:708 / 710
页数:2
相关论文
共 50 条
  • [21] Nevoid basal cell carcinoma (Gorlin) syndrome
    Gorlin, RJ
    GENETICS IN MEDICINE, 2004, 6 (06) : 530 - 539
  • [22] Dermatoscopic characteristics of acrochordon-like basal cell carcinomas in Gorlin-Goltz syndrome
    Feito-Rodriguez, Marta
    Sendagorta-Cudos, Elena
    Moratinos-Martinez, Marta
    Jose Gonzalez-Beato, Maria
    de Lucas-Laguna, Radl
    Pizarro, Angel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (05) : 857 - 861
  • [23] A woman with cutaneous basal-cell carcinomas and cysts of the jaws - The basal-cell nevus (Gorlin's) syndrome with multiple basal-cell carcinomas and odontogenic keratocysts.
    Epstein, Ervin H.
    Shepard, Jo-Anne O.
    Flotte, Thomas J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (04): : 393 - 401
  • [24] Gorlin Syndrome: Sequential Digital Dermoscopy of Palpebral Basal Cell Carcinomas in a Patient Treated with Vismodegib
    Mena-Vergara, Luis
    Silva-Astorga, Mariana
    Carrasco-Cancino, Carolina
    Munoz-Uslar, Leoncio
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2022, 12 (01):
  • [25] Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate- photodynamic therapy
    Basset-Seguin, N.
    Bissonnette, R.
    Girard, C.
    Haedersdal, M.
    Lear, J. T.
    Paul, C.
    Piaserico, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (05) : 626 - 632
  • [26] Treatment of Multiple Unresectable Basal Cell Carcinomas from Gorlin-Goltz Syndrome: A Case Report
    Ojevwe, Fidelis O.
    Ojevwe, Cindy D.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    Lin, Amy
    Kohlitz, Patrick
    ANTICANCER RESEARCH, 2015, 35 (03) : 1777 - 1781
  • [27] Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series
    Wescott, Raquel
    Samlowski, Wolfram
    CURRENT ONCOLOGY, 2023, 30 (10) : 9156 - 9167
  • [28] Phenotypic spectrum of a patient with Gorlin's syndrome and role of dermoscopy in the early detection of basal cell carcinomas
    Moreira, Catarina
    Santos, Paulo
    Azevedo, Filomena
    Morais, Paulo
    Castro, Miguel
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2015, 90 (03) : 416 - 419
  • [29] Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome and multiple basal cell carcinomas
    Piccerillo, Alfredo
    Di Stefani, Alessandro
    Costantini, Alessio
    Peris, Ketty
    DERMATOLOGIC THERAPY, 2021, 34 (05)
  • [30] Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream
    Ferreres, J. R.
    Macaya, A.
    Jucgla, A.
    Muniesa, C.
    Prats, C.
    Peyri, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, 20 (07) : 877 - 878